1. Home
  2. ZVIA vs PLYX Comparison

ZVIA vs PLYX Comparison

Compare ZVIA & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zevia PBC

ZVIA

Zevia PBC

N/A

Current Price

$1.22

Market Cap

126.3M

ML Signal

N/A

Logo Polaryx Therapeutics Inc. Common Stock

PLYX

Polaryx Therapeutics Inc. Common Stock

N/A

Current Price

$1.97

Market Cap

112.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ZVIA
PLYX
Founded
2007
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
126.3M
112.7M
IPO Year
2021
2025

Fundamental Metrics

Financial Performance
Metric
ZVIA
PLYX
Price
$1.22
$1.97
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
4
Target Price
$3.96
★ $7.50
AVG Volume (30 Days)
★ 362.9K
22.2K
Earning Date
11-04-2026
11-14-2026
Dividend Yield
N/A
N/A
EPS Growth
55.88
★ 77.53
EPS
★ N/A
N/A
Revenue
★ $161,259,000.00
N/A
Revenue This Year
$8.02
N/A
Revenue Next Year
$6.05
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 4.01
N/A
52 Week Low
$1.11
$1.85
52 Week High
$2.78
$9.18

Technical Indicators

Market Signals
Indicator
ZVIA
PLYX
Relative Strength Index (RSI) 36.29 46.50
Support Level $1.13 $2.03
Resistance Level $1.50 $2.21
Average True Range (ATR) 0.07 0.10
MACD -0.01 0.00
Stochastic Oscillator 9.23 34.89

Price Performance

Historical Comparison
ZVIA
PLYX

About ZVIA Zevia PBC

Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.

About PLYX Polaryx Therapeutics Inc. Common Stock

Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.

Share on Social Networks: